Bioventus Inc
NASDAQ:BVS
Bioventus Inc
Research & Development
Bioventus Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Research & Development
-$12.4m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Research & Development
-$62.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Research & Development
-$88.8m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-18%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Research & Development
-$369.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-20%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Research & Development
-$165.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-26%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Research & Development
-$96m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
What is Bioventus Inc's Research & Development?
Research & Development
-12.4m
USD
Based on the financial report for Sep 27, 2025, Bioventus Inc's Research & Development amounts to -12.4m USD.
What is Bioventus Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-2%
Over the last year, the Research & Development growth was 10%. The average annual Research & Development growth rates for Bioventus Inc have been 21% over the past three years , -2% over the past five years .
